Keywords: سیریتینیب; Ceritinib; Reversed-phase liquid chromatography with tandem mass spectrometry (LC-MS/MS); Fraction unbound in plasma; Fraction unbound in brain tissue; Brain tumor penetration; Unbound brain-to-plasma partition coefficient;
مقالات ISI سیریتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: سیریتینیب; Alectinib; ALK inhibitor; Ceritinib; EML4-ALK; NSCLC;
Keywords: سیریتینیب; Lung cancer; Intensive care; Targeted therapy; ALK gene rearrangement; Ceritinib; Clinical trials;
Keywords: سیریتینیب; ALK rearrangement; Brain metastases; Ceritinib; Crizotinib; NSCLC
ReviewDrug resistance in ALK-positiveNon-small cell lungcancer patients
Keywords: سیریتینیب; ALK; Point mutation; Crizotinib; Ceritinib; Alectinib; Lorlatinib;
ReviewOptimal management of ALK-positive NSCLC progressing on crizotinib
Keywords: سیریتینیب; Alectinib; ALK-TKI; Brigatinib; Ceritinib; Crizotinib; Non-small cell lung cancer;
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy
Keywords: سیریتینیب; Anaplastic lymphoma kinase; Carcinoma; Non-small-cell lung; Ceritinib; Drug resistance; Neoplasm;
Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R
Keywords: سیریتینیب; Anaplastic lymphoma kinase (ALK); Non-small cell lung cancer (NSCLC); Ceritinib; Crizotinib-resistant; G1202R;
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)
Keywords: سیریتینیب; Anaplastic lymphoma kinase; NSCLC; Ceritinib; Food-effect study;
Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)
Keywords: سیریتینیب; Acalabrutinib; Alectinib; Brigatinib; Ceritinib; Crizotinib; Dabrafenib; Dasatinib; Erlotinib; Gefitinib; Ibrutinib; Imatinib; Lorlatinib; Nilotinib; Osimertinib; Rociletinib; Trametinib; Vemurafenib;
Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer
Keywords: سیریتینیب; EML4-ALK; Ceritinib; KRCA-386;
EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer
Keywords: سیریتینیب; ALK-positive NSCLC; Resistance; Ceritinib; Epithelial-mesenchymal transition; HSP90 inhibition;
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review
Keywords: سیریتینیب; Acquired resistance; Alectinib; ALK inhibitor resistance; Ceritinib; Crizotinib;
Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity
Keywords: سیریتینیب; Inflammatory myofibroblastic tumor; ALK; ASP3026; Ceritinib; NF1; Hyaluronan;
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls
Keywords: سیریتینیب; ALK; NSCLC; ceritinib; crizotinib; indirect comparison;
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib
Keywords: سیریتینیب; Crizotinib; Alectinib; Ceritinib; I1171 missense mutation; ALK-rearranged non-small cell lung cancer; I1171N; I1171T; I1171S;
Traitement systémique des métastases cérébrales de cancer bronchique
Keywords: سیریتینیب; Chimiothérapie; Cisplatine; Erlotinib; Géfitinib; Afatinib; Crizotinib; Céritinib; Radiothérapie pancérébraleChemotherapy; Cisplatin; Erlotinib; Gefitinib; Afatinib; Crizotinib; Ceritinib; Whole brain radiotherapy
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
Keywords: سیریتینیب; Mutation; Lung cancer; Adenocarcinoma; MET; Exon 14; Amplification; PIK3CA; ALK; ROS1; Crizotinib; Ceritinib;
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis
Keywords: سیریتینیب; Alectinib; ALK; ALK-TKI; Ceritinib; Crizotinib; Non-small cell lung cancer;
Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors
Keywords: سیریتینیب; ALK rearranged; non-small-cell lung cancer; Ceritinib; Alectinib;
Future options for ALK-positive non-small cell lung cancer
Keywords: سیریتینیب; Alectinib; ALK; ALK-TKI; CNS metastases; Ceritinib; Crizotinib; Non-small cell lung cancer; Targeted therapy
Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)
Keywords: سیریتینیب; ABC; ATP-binding cassette; ALK; anaplastic lymphoma kinase; AUC; area under the plasma concentration-time curve; BBB; blood-brain barrier; BCRP; breast cancer resistance protein; Cmax; maximum drug concentration in plasma; EML4; echinoderm microtubule-ass